More about chloroquine and hydroxychloroquine, CEBM (updated 30th August 2020)
VERDICT The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - September 2, 2020 Category: Consumer Health News Source Type: news

TCMS Linked to Lower Burden of Ventricular Tachycardia Storm TCMS Linked to Lower Burden of Ventricular Tachycardia Storm
A pilot study in which transcutaneous magnetic stimulation was used to treat refractory ventricular tachycardia storm shows a lower burden of sustained and unsustained ventricular tachycardia after 48 hours.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - June 9, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news

More about chloroquine and hydroxychloroquine, CEBM
VERDICT: The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - June 1, 2020 Category: Consumer Health News Source Type: news

What Causes Tachycardia?
Discussion Tachycardia is a rapid heart rate that is above normal for age and level of exertion. Tachycardia is common, particularly sinus tachycardia due to normally encountered circumstances such as pain, fever or exercise. It is usually a normal physiologic process but sustained tachycardia often indicates a potentially abnormal underlying cause. Sinus tachycardia has a rapid heart rate with normal P waves and P-R intervals and variations from moment to moment and respiration. Generally it is not over 200 beats/minute. Vagal stimulation can slow the heart rate; this is a gradual slowing, not an abrupt slowing seen in ...
Source: PediatricEducation.org - March 23, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Heart condition can be cured with a quick blast of lung cancer therapy
Ventricular tachycardia is a major cause of sudden cardiac death, and kills more than 100,000 in the UK every year. Tests show the abnormal rhythm can be corrected with a pain-free blast of radiotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - February 15, 2020 Category: Consumer Health News Source Type: news

Meet the Brilliant Minds Behind the First ICD
Mirowski: From WWII to Sinai Hospital The story of how Mieczyslaw "Michel" Mirowski ended up in America where he conceived the idea of an implantable cardioverter-defibrillator (ICD) is almost as incredible as the invention itself, if not more so. Mirowski was born in Warsaw, Poland in 1924. He grew up among the large Jewish population of Warsaw at that time, but when the Nazis invaded Poland in 1939, 15-year-old Mirowski left his family and fled to Russia with a friend. He would be the only member of his family to survive World War II, according to a 2010Â&nb...
Source: MDDI - February 3, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Source Type: news

Arrhythmia & EP | Medscape Arrhythmia & EP | Medscape
Review in-depth clinical information, latest medical news, and guidelines about cardiac arrhythmias, including atrial fibrillation, paroxysmal tachycardia, ventricular tachycardia, and ventricular fibrillation. Read about diagnostic tests for arrhythmia and arrhythmia management. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news

Radiation Rx Might Ease a Dangerous Irregular Heart Beat
This irregular rhythm, called ventricular tachycardia (VT), occurs when the heart's lower chambers start to beat uncontrollably fast. Once it starts, it can kill within minutes. (Source: WebMD Health)
Source: WebMD Health - September 18, 2019 Category: Consumer Health News Source Type: news

VT Reduced With Single Radiation Treatment VT Reduced With Single Radiation Treatment
A noninvasive mapping and intervention approach for patients with refractory ventricular tachycardia opens a new frontier for those with no other treatment options and for whom SBRT represents the only final solution.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

BioSig Lands Licensing Deal with Mayo Clinic
BioSig Technologies and Mayo Clinic have joined forces once again, this time to develop a new product pipeline to support some of the more advanced features of BioSig's Pure EP System. Samuel Asirvatham, MD, Mayo Clinic's vice-chair of innovation and medical director of the electrophysiology (EP) laboratory, will lead the new development program. The company previously signed a 10-year collaboration agreement with Mayo Clinic in March 2017. "The new product that we intend to develop under the latest licensing will seek to significantly advance the current arrhythmia treatments," said Kenne...
Source: MDDI - September 16, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Periodic Limb Movements of Sleep Tied to Ventricular Tachycardia Periodic Limb Movements of Sleep Tied to Ventricular Tachycardia
Periodic limb movements in sleep with arousals are known to increase the risk for atrial fibrillation, but new research suggests they are also linked to increased risk for nonsustained ventricular tachycardia.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 27, 2019 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Sotera Wireless adds tools to patient monitoring system
Sotera Wireless said it has upgraded its ViSi Mobile patient monitoring system to detect atrial fibrillation, ventricular fibrillation and ventricular tachycardia, and to provide asystole analysis. Often asymptomatic, atrial fibrillation may remain undiagnosed until or even after the development of complications, such as stroke. Post-operative atrial fibrillation is the most common arrhythmia that occurs after both cardiac and noncardiac surgery and is associated with increased morbidity, longer hospital stays and higher hospital costs. ViSi Mobile was previously FDA-cleared to monitor continuous noninvasive blood pressure...
Source: Mass Device - March 6, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: 510(k) Blog Food & Drug Administration (FDA) Health Information Technology mHealth (Mobile Health) News Well Patient Monitoring Regulatory/Compliance Sotera Wireless Source Type: news

Study finds fault with ICD leads that Abbott inherited from St. Jude Medical
A review of FDA adverse event reports has revealed that some Abbott (NYSE:ABT) implantable cardioverter defibrillator (ICD) leads were much more likely than those made by Boston Scientific or Medtronic to fail due to internal insulation breaches (IBR). Researchers at the Minneapolis Heart Institute Foundation combed through the FDA MAUDE database from 2008 to 2018 for reports of IBR breaches and other ICD failures. They found that insulation breaches led to 93% of Abbott’s (formerly St. Jude Medical’s) Durata pacemaker lead failures. All 11 failures to treat ventricular tachycardia/ventricular fibrill...
Source: Mass Device - March 4, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Cardiac Assist Devices Cardiac Implants Featured Food & Drug Administration (FDA) News Well Abbott Boston Scientific Medtronic stjudemedical Source Type: news

Will Mobile ECPR Change How EMS Treats Cardiac Arrest?
“He not busy being born, is busy dying.”—Bob Dylan (1965) No one is busier dying than a patient in refractory ventricular fibrillation (RVF). These patients have exasperated EMS personnel for decades, and they, sadly, usually die. The treatment traditionally has been to administer ACLS for 30–45 minutes, and the lucky few who get a return of spontaneous circulation (ROSC) get admitted. The survival rate using this approach has been around 8%.1 But, with the advent of adult, extracorporeal membrane oxygenation (ECMO), the approach to these patients may be changing. JEMS: ECMO & ECPR The use of EC...
Source: JEMS Patient Care - February 2, 2019 Category: Emergency Medicine Authors: Ralph J. Frascone, MD, FACEP, FAEMS Tags: Exclusive Articles Cardiac & Resuscitation Top Story Source Type: news

Abbott launches FlexAbility cath ventricular tachycardia ablation trial
Abbott (NYSE:ABT) said yesterday that it launched a study aiming to evaluate ablation treatments for patients with ventricular tachycardia, touting it as the first such trial of its kind. In the trial, dubbed the Less-VT study, investigators will explore the safety and effectiveness of ablation with the Chicago-area medtech giant’s FlexAbility ablation catheter in treating monomorphic ventricular tachycardia in patients who are unresponsive to drug therapy. “For some patients with sustained monomorphic ventricular tachycardia, drug therapy is an ineffective treatment option. We want to build a body of clin...
Source: Mass Device - November 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Featured Abbott Source Type: news

Abbott Initiates Study to Evaluate Ablation as a Frontline Treatment for Patient's Suffering from a Common but Complex Cardiac Arrhythmia
LESS-VT Study is the first U.S. clinical trial to evaluate the safety and effectiveness of ablation treatment for patients with monomorphic ventricular tachycardia, a common heart rhythm disorder (Source: Abbott.com)
Source: Abbott.com - November 20, 2018 Category: Pharmaceuticals Source Type: news

New ablation treatment for ventricular tachycardia reaches deeper into heart muscle
(Loyola University Health System) Loyola Medicine is among two centers in the world offering a novel catheter ablation system intended to improve treatment outcomes for a life-threatening heart rhythm disorder called ventricular tachycardia (VT). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2018 Category: International Medicine & Public Health Source Type: news

Augmented reality may assist cardiologists plan and perform complex procedures
(Beth Israel Deaconess Medical Center) Jihye Jang, a PhD Candidate at the Cardiac Magnetic Resonance Center at Beth Israel Deaconess Medical Center, and colleagues assessed Augmented reality's potential to help cardiologists visualize myocardial scarring in the heart as they perform ventricular tachycardia ablation or other electrophysiological interventions. The team's findings, published in PLOS ONE, demonstrate that the new augmented reality technology confers a number of advantages. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2018 Category: International Medicine & Public Health Source Type: news

Variabilities in the Use of IV Epinephrine in the Management of Cardiac Arrest Patients
Animal studies in the 1960s first demonstrated the benefits of using epinephrine alongside external compressions and external shock to achieve return of spontaneous circulation (ROSC) in arrested and asphyxiated dogs.1–4 Since then, epinephrine has become integral to the performance of advanced cardiac life support (ACLS) care. The American Heart Association’s (AHA) recommendations in the Emergency Cardiovascular Care (ECC) Guidelines are that a standard dose of 1 mg of 1:10,000 epinephrine every 3–5 minutes “may be reasonable for patients with cardiac arrest.”5 No maximum total dose is deline...
Source: JEMS Patient Care - October 15, 2018 Category: Emergency Medicine Authors: Nidhish Lokesh, NREMT Tags: Exclusive Articles Cardiac & Resuscitation Source Type: news

Variabilities in the Use of IV Epinephrine in the Management of Cardiac Arrest Patients
Discussion The results show a lack of standardization in epinephrine dosing across large EMS systems around the world, in spite of the existence of standard guidelines such as the 2015 AHA CPR and ECC Guidelines.5 Dosing maximums, epinephrine drip use, dosing amount and frequency, and dosing distinction for rhythms not being more consistent across the board shows the current state of uncertainty that epinephrine administration is in at this time. The AHA ECC Guidelines don’t specify dosing maximums or about distinguish between v fib and other rhythms.5 In those two categories, responding agencies showed a lack of sta...
Source: JEMS Special Topics - October 15, 2018 Category: Emergency Medicine Authors: Nidhish Lokesh, NREMT Tags: Exclusive Articles Cardiac & Resuscitation Source Type: news

Ranolazine Doesn't Cut VT, VF, Death in High-Risk ICD Patients
TUESDAY, Sept. 18, 2018 -- For high-risk patients with implantable cardioverter-defibrillators (ICDs), ranolazine does not significantly reduce the risk of ventricular tachycardia (VT) or ventricular fibrillation (VF) requiring appropriate ICD... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 18, 2018 Category: Pharmaceuticals Source Type: news

3D virtual simulation gets to the 'heart' of irregular heartbeats
(Johns Hopkins Medicine) In a proof of concept study, scientists at Johns Hopkins report they have successfully performed 3D personalized virtual simulations of the heart to accurately identify where cardiac specialists should electrically destroy cardiac tissue to stop potentially fatal irregular and rapid heartbeats in patients with scarring in the heart. The retrospective analysis of 21 patients and prospective study of five patients with ventricular tachycardia, the researchers say, demonstrate that 3D simulation-guided procedures are worthy of expanded clinical trials. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 12, 2018 Category: International Medicine & Public Health Source Type: news

Chest pain drug falls short in preventing first episode of ventricular arrhythmia or death
(University of Rochester Medical Center) A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine (used to treat chest pain; brand name Ranexa ® ) was safe but didn't decrease the likelihood of the first occurrence of ventricular arrhythmias or death in this high-risk population. The drug did lower the risk for recurrent ventricular tachycardia by 30 percent, suggesting it could be a treatment option for this very sick population for which there are limited therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2018 Category: International Medicine & Public Health Source Type: news

Thermedical wins FDA nod for Durablate catheter trial
Thermedical said today that it won an investigational device exemption from the FDA for a clinical trial of its Durablate catheter for treating ventricular tachycardia. The Durablate catheter is designed to simultaneously inject hot saline and use radiofrequency energy to effect the ablation; the Thermedical claims that the method is 20 times more effective than conventional RF ablation. The Waltham, Mass.-based company said the 30-patient early feasibility study is designed for patients already implanted with an implantable cardioverter defibrillator who’ve also had a conventional VT ablation procedure tha...
Source: Mass Device - July 31, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Catheters Clinical Trials atrial fibrillation Thermedical Source Type: news

Bioelectronics: A New era in Medical Care Is on the Horizon
Bioelectronics, generally defined, isn't new. Doctors Rune Elmqvist and Ake Senning implanted the first pacemaker in 1958. FDA approved the first spinal cord stimulator (SCS) in 1989. While both solutions continue to help patients worldwide, smaller, more advanced technology has pushed bioelectronics into a new era. Researchers have developed novel methods to use electrical impulses to regulate the brain and/or nervous system, resulting in highly targeted, effective treatment. "While SCS benefits last as long as the device stimulates, and the pacemaker continually keeps the heart on path, we treat and hope to modify t...
Source: MDDI - July 25, 2018 Category: Medical Devices Authors: Heather R. Johnson Tags: Implants Electronics Source Type: news

A case of life-threatening loperamide toxicity
3 out of 5 stars Severe loperamide toxicity associated with the use of cimetidine to potentiate the “high.” Hughes A et al. AM J Emerg Med 2018 May 15 [Epub ahead of print] Reference The potential adverse effects of loperamide (Imodium) are often underestimated since, even though it is an opioid, it is available over-the-counter and has been since 1988. Loperamide is used to treat diarrhea. It acts on the mu-opioid receptors in the gut, decreasing gastric motility. It is rather effective at this. However at therapeutic doses (2-16 mg per day) it does not cause central opioid effects such as euphoria or rel...
Source: The Poison Review - May 24, 2018 Category: Toxicology Authors: Leon Gussow Tags: Medical imodium loperamide overdose toxicity Source Type: news

Marijuana Use Not Linked to Risk of Arrhythmias After Acute MI
WEDNESDAY, May 9, 2018 -- For patients with acute myocardial infarction (AMI), marijuana use is not associated with increased risk of ventricular tachycardia/ventricular fibrillation (VT/VF) or cardiac arrest, according to a study presented at the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 9, 2018 Category: Pharmaceuticals Source Type: news

Infographic: The heart out of rhythm
Learn more about?ventricular tachycardia. Other health tip infographics: mayohealthhighlights.startribune.com? (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 2, 2018 Category: Databases & Libraries Source Type: news

Could BioSig Play a Vital Role in the Bioelectronics Market?
BioSig Technologies is hoping to make an impact in the $4.6 billion electrophysiology (EP) market with its first product offering. The Santa Monica, CA-based company is developing the Pure EP system, a surface electrocardiogram and intracardiac multichannel device. BioSig filed said it filed for FDA clearance of the Pure EP system in late March. Once the company receives FDA clearance then it would turn its attention toward gaining regulatory clearance in Europe. “We feel like we’ve made a very robust submission to FDA,” Ken Londoner, founder and CEO of BioSig, told MD+DI. The Pure EP Syste...
Source: MDDI - April 6, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news

Fatal flecainide intoxication in a 17-year-old girl - Dokter M, Talarico G, Armbrust S, Below E, Bockholdt B.
A  17-year-old girl was found vomiting and somnolent at home and was taken to a hospital. The girl initially presented with ventricular tachycardia with broad QRS complexes which was very difficult to control. During the course a subsequent cardiogenic sh... (Source: SafetyLit)
Source: SafetyLit - April 2, 2018 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Medical News Today: What is torsades de pointes?
Torsades de pointes is an uncommon type of ventricular tachycardia that can be potentially life-threatening. Learn more about the causes and diagnosis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 15, 2018 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Stereotactic Body Radiation Can Cut Ventricular Tachycardia
Reduction from baseline of 99.9 percent in episodes of ventricular tachycardia in five patients (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 14, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Pathology, Pulmonology, Radiology, Journal, Source Type: news

Focused Radiation May Nearly Erase Ventricular Tachycardia
(MedPage Today) -- Small case series in high-risk patients is promising for noninvasive tx (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 13, 2017 Category: Cardiology Source Type: news

A ‘ Game Changer ’ for Patients With Irregular Heart Rhythm
Rapid, erratic heartbeats — called ventricular tachycardia — can lead to sudden death. An experimental radiation treatment has eased the condition in five patients. (Source: NYT Health)
Source: NYT Health - December 13, 2017 Category: Consumer Health News Authors: GINA KOLATA Tags: Defibrillators Heart Radiation Medical Devices Source Type: news

Benefit of ECMO in Resuscitation from Refractory V Fib Cardiac Arrest
  The dawn of a new era Although ventricular tachycardia/ventricular fibrillation (v tach/v fib) constitutes only 25-35% of all cardiac arrests, more than 80% of all cardiac arrest survivors with favorable neurological function present with v tach/v fib.1,2 (See Figure 1, p. 12.) Despite that, only one third (approximately 30%) of patients presenting initially with v tach/v fib survive to hospital discharge with good neurological function. Compared to the other presenting rhythms (asystole and pulseless electrical activity) v tach/v fib is associated with the highest survival and stands out as the most important pos...
Source: JEMS Patient Care - December 1, 2017 Category: Emergency Medicine Authors: Demetris Yannopoulos, MD Tags: Patient Care Cardiac & Resuscitation Source Type: news

Benefit of ECMO in Resuscitation from Refractory V Fib Cardiac Arrest
  The dawn of a new era Although ventricular tachycardia/ventricular fibrillation (v tach/v fib) constitutes only 25-35% of all cardiac arrests, more than 80% of all cardiac arrest survivors with favorable neurological function present with v tach/v fib.1,2 (See Figure 1.) Despite that, only one third (approximately 30%) of patients presenting initially with v tach/v fib survive to hospital discharge with good neurological function. Compared to the other presenting rhythms (asystole and pulseless electrical activity) v tach/v fib is associated with the highest survival and stands out as the most important positive p...
Source: JEMS Patient Care - December 1, 2017 Category: Emergency Medicine Authors: Demetris Yannopoulos, MD Tags: Patient Care Cardiac & Resuscitation Source Type: news

Delayed onset of atrial fibrillation and ventricular tachycardia after an automobile lightning strike - Drigalla D, Essler SE, Stone CK.
BACKGROUND: Lightning strike is a rare medical emergency. The primary cause of death in lightning strike victims is immediate cardiac arrest. The mortality rate from lightning exposure can be as high as 30%, with up to 70% of patients left with significant... (Source: SafetyLit)
Source: SafetyLit - September 13, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Is BioSig for Real This Time With Its Pure EP?
A couple years ago, BioSig Technologies, Inc. was poised to apply for FDA clearance to market its technology to improve treatment of atrial fibrillation and ventricular tachycardia. Then its scientific advisors advised the Minneapolis company to put more work into that technology, a hardware-software combination designed to present clearer signals during electrophysiology studies and catheter ablation. The technology, Pure EP, is designed to cut through the background noise of the lab and its equipment during cardiac recordings, enabling physicians to target and neutralize the areas of the heart that are causing atria...
Source: MDDI - September 7, 2017 Category: Medical Devices Authors: Nancy Crotti Tags: MD & M Minneapolis R Software Source Type: news

Milestone Pharmaceuticals Closes $55 Million Series C Financing
Proceeds to Fund Etripamil Phase 3 Development and Pre-Launch Market Development MONTREAL, August 1, 2017 -- (Healthcare Sales & Marketing Network) -- Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today anno... Biopharmaceuticals, Venture Capital, Personnel Milestone Pharmaceuticals, etripamil, supra-ventricular tachycardia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 1, 2017 Category: Pharmaceuticals Source Type: news

Ablation of Ventricular Tachycardia in Patients With MitraClip Ablation of Ventricular Tachycardia in Patients With MitraClip
Patients with mitral regurgitation are increasingly being treated with a MitraClip device. Is it feasible and safe to perform catheter ablation for ventricular tachycardia in these patients?Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 29, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Chest Pain Drug Decreases Common Arrhythmias
A drug approved to treat chest pain reduces the incidence of a common arrhythmia called ventricular tachycardia in patients with an implantable cardioverter defibrillator, according to a study presented today at the Heart Rhythm Society ’s annual meeting. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - May 13, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Add-on Tx Cuts Exercise-Induced Arrhythmia in Genetic CPVT
(MedPage Today) -- Flecainide helps in catecholaminergic polymorphic ventricular tachycardia (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 11, 2017 Category: Cardiology Source Type: news

HRS 2017: Two-year registry data on Boston Scientific ’ s S-ICD
Data from a long-term post-approval registry study of the S-ICD subcutaneous pacemaker made by Boston Scientific (NYSE:BSX) showed high successful implantation rates and “acceptable” short-term complication rates, researchers said today at the annual Heart Rhythm Society conference in Chicago. The study looked at data from 1,637 S-ICD patients who met the criteria for implantable cardioverter defibrillator implantation, passed at least 1 electrocardiogram screening vector and had a life expectancy of more than 1 year. The mean follow-up time was 2 years and the study plans to follow patients out ...
Source: Mass Device - May 11, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Boston Scientific Cardiac Rhythm Management hrs2017 Source Type: news

Zoll Medical wins Health Canada nod for next-gen AEDs
Zoll Medical said this week it won approval from Health Canada for its Zoll AED 3 and Zoll AED 3 BLS automated external defibrillators and launched them in the region. Both newly-cleared AEDs provide real-time feedback to communicate appropriate timing for effective CPR through audible and visual prompts, which the Chelmsford, Mass.-based company said can be critical to a patient’s survival. “We are extremely excited to add the Zoll AED 3 and the Zoll AED 3 BLS to our portfolio of automated external defibrillators. With the addition of these new devices, we are able to offer our public access and BLS ...
Source: Mass Device - March 23, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Regulatory/Compliance Resuscitation Zoll Medical Corp. Source Type: news

BioSig inks strategic partnership deal with Mayo Clinic
BioSig Technologies (OTCQB: BSGM) said today it inked a 10-year strategic agreement with the Mayo Clinic to develop advanced clinical features and applications for its Pure EP system. The new agreement expands on an earlier Advanced Clinical Research Program between BioSig and the Mayo clinic signed last March. “We are pleased to strengthen and broaden our relationship with Mayo Clinic and Mayo Ventures to grow our innovation capabilities and deliver superior medical technology,” founder & exec chair Kenneth Londoner said in a prepared statement. BioSig said it will work with Dr. Samuel Asirv...
Source: Mass Device - March 17, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Research & Development BioSig Technologies Source Type: news

Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer
MONTREAL, March 7, 2017 -- (Healthcare Sales & Marketing Network) -- Milestone Pharmaceuticals USA, Inc., a clinical stage cardiovascular company, today announced the appointment of Joseph G. Oliveto as President and Chief Executive Officer, effective imm... Biopharmaceuticals, Cardiology, Personnel Milestone Pharmaceuticals, etripamil, paroxysmal supra-ventricular tachycardia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 7, 2017 Category: Pharmaceuticals Source Type: news

Francesca ’s story: Beating a heart tumor
Although her parents were warned she might not breathe when she was born, the moment Francesca Durkos came into this world, she let out a gutsy cry. “It was music to our ears,” says her mom. Michelle Carino Durkos was 40 weeks pregnant when she learned there was a tumor attached to her unborn daughter’s heart — a tumor so large that doctors near her home in Pensacola, Florida, were unsure if the baby would live. “It was a shock, because at 20 weeks everything was normal,” says Michelle. “We had a wonderful ultrasound; we saw all four chambers.” Yet, call it a mother’s i...
Source: Thrive, Children's Hospital Boston - February 1, 2017 Category: Pediatrics Authors: Emily Williams Tags: Our Patients’ Stories cardiac fibroma cardiac tumor Department of Cardiac Surgery Department of Cardiology Dr. Pedro del Nido Dr. Tal Geva echocardiogram ECMO Fetal Cardiology Program heart tumor neona ultrasound Source Type: news

BioSig seeks funding in the EU
BioSig Technologies (OTCQB: BSGM) said today it will engage in an institutional investor roadshow in the EU as it seeks funding for its proprietary Pure electrophysiology platform. The company is developing a cardiac signal acquisition and display system which is designed to assist electrophysiologists in making clinical decisions for patients with abnormal heart rates and rhythms, including atrial fibrillation and ventricular tachycardia. Minneapolis, Minn.-based BioSig said it will tour “major EU financial centers” between Feb. 27 and March 3, with board chair Kenneth Londoner delivering presentatio...
Source: Mass Device - January 30, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular BioSig Technologies Source Type: news

Thermedical raises $3m for tissue ablation device
Thermedical raised $3 million in a new round of funding, according to regulatory filings. The private company is developing a treatment for ventricular tachycardia, an irregular heartbeat that can result in sudden cardiac arrest, and a treatment for soft tissue conditions, including liver, kidney, lung and uterine tumors. The company’s ablation system uses saline-enhanced radio frequency, according to Thermedical, to overcome the challenges of traditional ablation tools and to create large, controlled, symmetrical lesions.  The new round, which had its 1st sale on Jan. 13, will bring $700,000 to the company for ...
Source: Mass Device - January 25, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Cardiovascular Funding Roundup Thermedical Source Type: news

Clinical trial testing new technique to treat life-threatening ventricular tachycardia
A landmark clinical trial is evaluating a new procedure to treat a life-threatening heart rhythm disorder called ventricular tachycardia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 23, 2017 Category: Science Source Type: news